New Preventive for Bisphosphonate-Related Osteonecrosis of the Jaw Is in Development
Researchers at the University of California, Los Angeles, School of Dentistry have developed a topical medication designed to prevent or minimize the effects of bisphosphonate-related osteonecrosis of the jaw (BRONJ), an uncommon but serious side effect among those taking bisphosphonates to slow bone loss. The new medication showed efficacy in reducing BRONJ-caused jawbone lesions and gingival inflammation among mice. Results were published in eLife. The UCLA researchers are applying to the United States Food and Drug Administration for permission to begin human clinical trials. Click here to read more.
